-

11:04:32 PM

TTOO Stock News

TTOO - T2 Biosystems Inc

09/19/23 9:00 AM

Nasdaq : TTOO

clinical trial

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today

RHEA-AI

neutral

09/15/23 4:05 PM

Nasdaq : TTOO

T2 Biosystems Reports Granting of Inducement Award

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees. The awards were made on September 7, 2023, under the T2 Biosystems’

RHEA-AI

very positive

09/07/23 4:05 PM

Nasdaq : TTOO

conferencesacquisition

T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place

RHEA-AI

neutral

08/28/23 8:30 AM

Nasdaq : TTOO

T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today praised

RHEA-AI

neutral

08/09/23 8:30 AM

Nasdaq : TTOO

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August

RHEA-AI

neutral

08/07/23 4:05 PM

Nasdaq : TTOO

earnings

T2 Biosystems Announces Second Quarter 2023 Financial Results

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader

RHEA-AI

neutral

07/31/23 8:30 AM

Nasdaq : TTOO

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension

RHEA-AI

neutral

07/28/23 8:30 AM

Nasdaq : TTOO

conferences

T2 Biosystems to Attend Upcoming Investor Conferences

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2023: Canaccord Genuity Annual

RHEA-AI

neutral

07/24/23 4:05 PM

Nasdaq : TTOO

conferencesearnings

T2 Biosystems to Report Second Quarter 2023 Financial Results on August 7, 2023

T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2023 after market close Monday, August 7,

RHEA-AI

neutral

07/21/23 4:05 PM

Nasdaq : TTOO

T2 Biosystems Reports Granting of Inducement Award

T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to fourteen new employees. The awards were made on June 26, 2023, under the T2 Biosystems’ Inducement

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

TTOO Data

IndustrySmall Arms, Ordnance, and Ordnance Accessories Manufacturing
Websitehttp://www.t2biosystems.com/
Security nameT2 Biosystems Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Small Arms
- Ordnance
- and Ordnance Accessories Manufacturing
CountryUS

About T2 Biosystems Inc

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www